Onconova Therapeutics (NASDAQ:ONTX) received a $6.00 price target from research analysts at HC Wainwright in a report issued on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 337.96% from the stock’s previous close.

A number of other research analysts have also weighed in on the company. Zacks Investment Research lowered Onconova Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday. Maxim Group set a $6.00 price objective on Onconova Therapeutics and gave the stock a “buy” rating in a report on Thursday, November 9th. Finally, ValuEngine raised Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Onconova Therapeutics currently has an average rating of “Hold” and an average price target of $7.33.

Shares of Onconova Therapeutics (NASDAQ:ONTX) opened at $1.37 on Tuesday. Onconova Therapeutics has a 52 week low of $1.36 and a 52 week high of $3.88.

Onconova Therapeutics (NASDAQ:ONTX) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.73) by $0.02. The business had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.29 million. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 2,855.94%. analysts forecast that Onconova Therapeutics will post -2.82 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. 683 Capital Management LLC boosted its stake in Onconova Therapeutics by 21.0% in the third quarter. 683 Capital Management LLC now owns 375,000 shares of the biopharmaceutical company’s stock worth $641,000 after buying an additional 65,140 shares in the last quarter. Sabby Management LLC lifted its position in Onconova Therapeutics by 104.0% in the second quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock valued at $1,693,000 after purchasing an additional 399,640 shares during the last quarter. Tyndall Capital Partners L P lifted its position in Onconova Therapeutics by 91.4% in the second quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock valued at $2,154,000 after purchasing an additional 476,190 shares during the last quarter. Vanguard Group Inc. lifted its position in Onconova Therapeutics by 58.4% in the second quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock valued at $190,000 after purchasing an additional 32,418 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in Onconova Therapeutics by 27.2% in the fourth quarter. Renaissance Technologies LLC now owns 122,700 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 26,200 shares during the last quarter. 25.44% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/12/onconova-therapeutics-ontx-pt-set-at-6-00-by-hc-wainwright.html.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Receive News & Ratings for Onconova Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.